Loading…
Charles River Laboratories International, Inc. is projected to rise to $310.17 by 2027, a +32% move from its current price of $234.62. CRL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $229.24 | $234.72 | $240.33 | +0.04% |
| Aug 2 | $227.10 | $234.81 | $242.79 | +0.08% |
| Aug 3 | $225.49 | $234.91 | $244.72 | +0.12% |
| Aug 4 | $224.16 | $235.01 | $246.37 | +0.16% |
| Aug 5 | $223.01 | $235.10 | $247.85 | +0.21% |
| Aug 6 | $221.98 | $235.20 | $249.21 | +0.25% |
| Aug 7 | $221.04 | $235.30 | $250.47 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $221.04 | $235.30 | $250.47 | +0.29% |
| Week 2 | $216.02 | $235.97 | $257.77 | +0.58% |
| Week 3 | $212.38 | $236.65 | $263.70 | +0.87% |
| Week 4 | $209.46 | $237.33 | $268.92 | +1.16% |
| Week 5 | $206.98 | $238.02 | $273.71 | +1.45% |
| Week 6 | $204.83 | $238.70 | $278.18 | +1.74% |
| Week 7 | $202.92 | $239.39 | $282.42 | +2.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.
The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services.
The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.
Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories International, Inc. (CRL) trades at $234.62 per share and has a market capitalization of $11.3B, ranking 793.
The latest single-year forecast for 2026 shows an average price of $234.62 with a min of $149.93 and a max of $311.92, with a 0% ROI and a NEUTRAL sentiment.
From 2027 onward, the forecast turns bullish, with 2027 to 2035 averages rising from $310.17 to $1,017.98, while the 2040 and 2050 forecasts project stronger upside toward $1,766.69 and $4,040.30 respectively. This long-range view implies substantial upside potential, but these are estimates and not guarantees.
A major floor 36.1% below — a decisive break under it would weaken the trend.
The nearest floor, 22.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 18.4% above — clearing it would confirm fresh momentum.
Key CRL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $232.15 | Buy | $232.60 | Buy |
| MA 10 | $227.22 | Buy | $229.93 | Buy |
| MA 20 | $228.61 | Buy | $225.03 | Buy |
| MA 50 | $202.92 | Buy | $209.44 | Buy |
| MA 100 | $185.72 | Buy | $196.80 | Buy |
| MA 200 | $186.90 | Buy | $187.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.02 | Neutral |
| Stoch RSI (14) | 48.83 | Neutral |
| CCI (20) | 91.62 | Neutral |
| Williams %R (14) | -26.74 | Info |
| MACD (12,26,9) | -0.70 | Sell |
| ROC (12) | 1.47 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 73.26 | Neutral |
| TRIX (15) | 0.59 | Buy |
| Awesome (5,34) | 15.42 | Buy |
| Ultimate (7,14,28) | 64.46 | Neutral |
| Momentum (10) | 5.46 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 238.13 | Sell |
| ADX (14) | 28.02 | Buy |
| ATR (14) | 4.37 | Info |
The 30-day technical picture is BULLISH.
RSI14 is 60, indicating room to move higher but not overbought. The stock sits above the SMA50 of $202.92 and the SMA200 of $186.90, with immediate support at $181.56 and resistance at $240.43.
The 30-day range spans $200.80 to $274.14, and the stock’s annualized volatility stands at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $149.93 | $234.62 | $311.92 | 0% | Neutral | |
| $250.39 | $310.17 | $404.29 | +32% | Bullish | |
| $274.33 | $348.12 | $469.02 | +48% | Bullish | |
| $337.08 | $436.29 | $603.22 | +86% | Bullish | |
| $450.01 | $592.67 | $837.48 | +153% | Bullish | |
| $490.49 | $656.25 | $945.13 | +180% | Bullish | |
| $549.59 | $746.16 | $1,093.12 | +218% | Bullish | |
| $625.94 | $861.52 | $1,281.83 | +267% | Bullish | |
| $643.48 | $897.20 | $1,354.10 | +282% | Bullish | |
| $721.13 | $1,017.98 | $1,556.89 | +334% | Bullish | |
| $1,183.75 | $1,766.69 | $2,856.85 | +653% | Bullish | |
| $2,463.76 | $4,040.30 | $7,089.72 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $149.93 | $234.62 | $273.33 | +0.00% |
| August 2026 | $200.56 | $234.72 | $280.60 | +0.04% |
| September 2026 | $206.64 | $243.58 | $294.60 | +3.77% |
| October 2026 | $210.05 | $249.03 | $303.98 | +2.24% |
| November 2026 | $207.80 | $247.54 | $304.42 | -0.60% |
| December 2026 | $210.58 | $251.94 | $311.92 | +1.78% |
Click any year to see its month-by-month CRL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRL to range from $149.93 to $311.92 through 2026. The $234.62 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CRL price prediction for 2027 points to an average of $310.17 (low $250.39, high $404.29) — a potential gain of +32% on today's $234.62. Buyers look set to stay in control over this stretch.
In 2028, CRL is projected to trade between $274.33 and $469.02, averaging $348.12 — a potential gain of +48% from today's $234.62. That is up +12% on the projected 2027 average. Momentum favours further upside here.
Charles River Laboratories International, Inc.'s 2029 outlook centres on $436.29, within a $337.08 to $603.22 range. That is up +25% on the projected 2028 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CRL could reach as high as $837.48, with a base case around $592.67 and support toward $450.01 — roughly +153% from $234.62. Momentum favours further upside here.
Expect CRL to range from $490.49 to $945.13 through 2031. The $656.25 average target implies a +180% move from current prices. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CRL price prediction for 2032 points to an average of $746.16 (low $549.59, high $1,093.12) — a potential gain of +218% on today's $234.62. Momentum favours further upside here.
In 2033, CRL is projected to trade between $625.94 and $1,281.83, averaging $861.52 — a potential gain of +267% from today's $234.62. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Charles River Laboratories International, Inc.'s 2034 outlook centres on $897.20, within a $643.48 to $1,354.10 range. That is up +4% on the projected 2033 average. That marks a +282% change versus current levels. Momentum favours further upside here.
By 2035, CRL could reach as high as $1,556.89, with a base case around $1,017.98 and support toward $721.13 — roughly +334% from $234.62. Buyers look set to stay in control over this stretch.
Expect CRL to range from $1,183.75 to $2,856.85 through 2040. The $1,766.69 average target implies a +653% move from current prices. That is up +74% on the projected 2035 average. Momentum favours further upside here.
The CRL price prediction for 2050 points to an average of $4,040.30 (low $2,463.76, high $7,089.72) — a potential gain of +16.2x on today's $234.62. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRL today (≈ 4.262211 CRL) could be worth
$17,220.6
+$16,220.6 (+1622%) by 2050 · US Dollar
Based on the average projected CRL price of $4,040.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRLwould be worth at today's price.
$1,000 invested in CRL on Jul 30, 2025 (≈ 5.675691 CRL) would be worth
$1,331.63
+$331.63 (+33.2%) today · 1.33× · US Dollar
Based on a CRL entry price of $176.19 vs. today's $234.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $229.29 | $1,023.25 | +2.3% |
| 1 month ago | $226.79 | $1,034.53 | +3.5% |
| 3 months ago | $165.78 | $1,415.25 | +41.5% |
| 6 months ago | $210.48 | $1,114.69 | +11.5% |
| 1 year ago | $176.19 | $1,331.63 | +33.2% |
| All time (5.0y) ago | $405.6 | $578.45 | -42.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRL forecast.
Our base-case forecast reaches $470.00 around 2030.
Implied market cap at $470.00: $22.64B
The multi-year forecast shows substantial upside, with the average price rising year by year. The 2026 average is $234.62, rising to $310.17 in 2027 and $348.12 in 2028, with $436.29 in 2029 and $592.67 in 2030.
By 2035, the average reaches $1,017.98, continuing a bullish trajectory through 2040 at $1,766.69 and 2050 at $4,040.30. The forecast also shows rising maximums: $2,856.85 in 2040 and $7,089.72 in 2050. ROI progresses from 0% in 2026 to 32.2% in 2027, 48.4% in 2028, 86% in 2029, 152.6% in 2030, 333.9% in 2035, 653% in 2040, and 1622.1% in 2050, with a bullish sentiment from 2027 onward.
These are forward-looking estimates and carry inherent uncertainty and risk. Investors should view them as illustrative projections rather than guarantees of future results.
Tap a question to reveal the answer.
2030 min $450.01, avg $592.67, max $837.48; ROI 152.6%; sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward with increasing averages (2027 $310.17, 2028 $348.12, 2029 $436.29, 2030 $592.67, 2035 $1,017.98, 2040 $1,766.69, 2050 $4,040.30) and rising ROIs (32.2% in 2027 up to 1622.1% by 2050). The 2026 view is Neutral with a 0% ROI.
Yes. The 2035 forecast shows an average of $1,017.98 with a high of $1,556.89, indicating the possibility of crossing $1,000 in the mid-2030s and a bullish overall trajectory.
Current price is $234.62 per share and market cap is $11.3B.
Sentiment is BULLISH; RSI14 is 60. SMA50 is $202.92; SMA200 is $186.90. Support is $181.56 and resistance is $240.43. The 30-day range is $200.80 to $274.14; annualized volatility is 50%.
Charles River Laboratories International, Inc. Community Discussion
0Share your Charles River Laboratories International, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.